肾病综合征；利妥昔单抗是成人激素依赖型微小病变病和局灶节段性肾小球硬化症治疗中的曙光吗？
Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?
作者信息
Kronbichler Andreas, Mayer Gert
机构信息
Medical University Innsbruck, Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck, Austria.
出版信息
J Nephropathol. 2014 Jan;3(1):1-3. doi: 10.12860/jnp.2014.01. Epub 2014 Jan 1.
Abstract
Implication for health policy/practice/research/medical education: Reports on patients with steroid-dependent nephrotic syndrome and underlying minimal change disease or focal segmental glomerulosclerosis have shown promising results. There is a strong need for more trials conducted in a prospective, controlled manner to clearly recommend rituximab therapy in this indication on a regular basis.
摘要
对卫生政策/实践/研究/医学教育的启示：关于依赖类固醇的肾病综合征及潜在微小病变病或局灶节段性肾小球硬化症患者的报告已显示出有前景的结果。迫切需要以前瞻性、对照方式开展更多试验，以便定期明确推荐利妥昔单抗用于这一适应症的治疗。
相似文献
1
Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?
J Nephropathol. 2014 Jan;3(1):1-3. doi: 10.12860/jnp.2014.01. Epub 2014 Jan 1.
2
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
Nephron Clin Pract. 2014;128(3-4):277-82. doi: 10.1159/000368590. Epub 2014 Nov 8.
3
Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.
Glomerular Dis. 2023 Aug 18;3(1):211-219. doi: 10.1159/000533695. eCollection 2023 Jan-Dec.
4
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Autoimmun Rev. 2020 Nov;19(11):102671. doi: 10.1016/j.autrev.2020.102671. Epub 2020 Sep 15.
5
Electron microscopic findings suggestive of focal and segmental glomerulosclerosis in patients with steroid-resistant nephrotic syndrome.
Ultrastruct Pathol. 2019;43(1):6-12. doi: 10.1080/01913123.2019.1584258. Epub 2019 Mar 5.
6
Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
Wien Klin Wochenschr. 2013 Jun;125(11-12):328-33. doi: 10.1007/s00508-013-0366-7. Epub 2013 Apr 27.
7
Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
J Pediatr. 2018 Jun;197:191-197.e1. doi: 10.1016/j.jpeds.2018.01.008. Epub 2018 Apr 18.
8
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
Nephrology (Carlton). 2019 Dec;24(12):1241-1247. doi: 10.1111/nep.13554. Epub 2019 May 1.
9
Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Nephrol Dial Transplant. 2015 Jan;30(1):96-106. doi: 10.1093/ndt/gfu267. Epub 2014 Aug 13.
10
Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
Expert Opin Investig Drugs. 2018 Nov;27(11):839-879. doi: 10.1080/13543784.2018.1540587. Epub 2018 Oct 30.
引用本文的文献
1
Metformin and diabetic kidney disease: a mini-review on recent findings.
Iran J Pediatr. 2014 Oct;24(5):565-8. Epub 2014 Sep 12.
本文引用的文献
1
Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
Wien Klin Wochenschr. 2013 Jun;125(11-12):328-33. doi: 10.1007/s00508-013-0366-7. Epub 2013 Apr 27.
2
Renal involvement in autoimmune connective tissue diseases.
BMC Med. 2013 Apr 4;11:95. doi: 10.1186/1741-7015-11-95.
3
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
Kidney Int. 2013 Mar;83(3):511-6. doi: 10.1038/ki.2012.444. Epub 2013 Jan 16.
4
Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
Nephrol Dial Transplant. 2013 May;28(5):1225-32. doi: 10.1093/ndt/gfs515. Epub 2012 Dec 13.
5
Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Pediatr Nephrol. 2013 Feb;28(2):257-64. doi: 10.1007/s00467-012-2319-1. Epub 2012 Oct 10.
6
Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
Nephrol Dial Transplant. 2012 Mar;27(3):1083-9. doi: 10.1093/ndt/gfr405. Epub 2011 Aug 1.
7
Prevention and treatment of systemic glucocorticoid side effects.
Int J Dermatol. 2010 Mar;49(3):239-48. doi: 10.1111/j.1365-4632.2009.04322.x.
8
Rituximab in refractory nephrotic syndrome.
Pediatr Nephrol. 2010 Mar;25(3):461-8. doi: 10.1007/s00467-009-1376-6. Epub 2009 Dec 23.
9
Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells.
Nat Clin Pract Rheumatol. 2009 Feb;5(2):80-2. doi: 10.1038/ncprheum0983. Epub 2008 Dec 17.
Zotero 插件